Diana Escobar Azusa Pacific University. Authors: Thiele, Thomas, Kathleen Selleng, Sixten Selleng, Andreas Greinacher, &Tamam Bakchoul July 2013 Source:

Slides:



Advertisements
Similar presentations
Coagulopathy and blood component transfusion in trauma
Advertisements

Heather D. Mannuel, MD, MBA March 12, 2008
Adverse Effects of Blood Transfusion. Adverse Effects of Blood Transfusion ANY unfavorable consequence is considered an adverse effect of blood transfusion.
Hemorrhagic diseases. Lesions of the blood vessels Lesions of the blood vessels Abnormal platelets Abnormal platelets Abnormalities in the coagulation.
BLEEDING DISORDERS AN OVERVIEW WITH EMPHASIS ON EMERGENCIES.
LHD Logo Venous Thromboembolism Reducing the Risk DATE.
ECMO in CRRT – What are the Data?
Blood Components Dosage And Their Administration
Sickle Cell Disease: Core Concepts for the Emergency Physician and Nurse Acute Chest Syndrome Spring 2013.
STROKE & PREGNANCY By Judith Barnaby, Stroke CNS Reviewed by Dr. Bayer, Stroke Neurologist, St. Michael’s Hospital.
Tessa Bandhan. Question 1 A 3 year old girl known to have sickle cell disease (Hb SS) presents to the Emergency Room with a 2 day history of weakness.
Venous Thromboembolism Prevention August Venous Thromboembloism Prevention 2 Expected Practice  Assess all patients upon admission to the ICU for.
Best Practices in Meeting NPSG 3E-Anticoagulation Requirements MaryAnne Cronin, PharmD Assistant Director of Pharmacy Glen Cove Hospital.
Hemostatic System - general information Normal hemostatic system –vessel wall –circulating blood platelets –blood coagulation and fibrynolysis Platelets.
Islam Mohammad Shehata 2010 Department of I.C.U.and Anesthesia.
Leanna R. Miller, RN, MN, CCRN-CSC, PCCN-CMC, CNRN, CEN, NP Education Specialist LRM Consulting Nashville, TN.
Haemostasis Tiffany Shaw MBChB II Haemostasis Pathway Injury Collagen exposure Tissue Factor Platelet adhesion Coagulation Cascade Release reaction.
Cristy M. Thomas FNP-BC University of Nevada School of Medicine University Medical Center, Las Vegas NV Nevada’s Only Level 1 Adult Trauma, Level 2 Pediatric.
IMMUNE THROMBOCYTOPENIA Cathy Payne MSN, ACNP-BC Hematology/Oncology Nurse Practitioner Ironwood Cancer and Research Centers.
MTP Octaplex rFVIIa Calgary. Massive Transfusion Protocol.
Systemic inflammatory response syndrome score at admission independently predicts mortality and length of stay in trauma patients. by R2 黃信豪.
Chemotherapy/ Biotherapy for Hematology Disease Processes.
ITP Immune (Idiopathic) Thrombocytopenic Purpura AM Report 5/25/2010.
Week 7: Fibrinolysis and Thrombophilia Secondary fibrinolysis Secondary fibrinolysis Primary fibrinolysis Primary fibrinolysis Plasminogen Plasminogen.
THROMBOCYTOPENIA - reduced platelet count -. First of all.. what are platelets? Platelets: tiny cells that circulate in the blood and whose function is.
Autoimmune Idiopathic Thrombocytopenic Purpura (ITP) Nicola Davis.
NURS 1950 Pharmacology I 1.  Objective 1: identify general reasons anticoagulants are given 2.
Study Guide Guide for Patients Undergoing Anticoagulant Therapy.
The Clinical Guide “A Guide to Implementing Renal Best Practice in Haemodialysis“ Chapter 5: Anticoagulation Team Leader: Angela Henson Co-authors: Franta.
Blood Transfusion Done by : Mrs.Eman Rizk. Definition ( Blood Transfusion ) Is the process of transferring blood or blood-based products from one person.
VTE Venous ThromboEmbolism. VTE – aims of this module To define the terms associated with VTE and offer maximum care to treat patients. To define the.
Safety of Perioperative Aspirin Use in Pancreatic Surgery Andrea M Wolf, Jordan M Winter, Salil D Gabale, Eugene P Kennedy, Ernest L Rosato, Harish Lavu,
DVT Prevention and Anticoagulant Management
The Clotting Cascade and DIC Karim Rafaat, MD. Coagulation Coagulation is a host defense system that maintains the integrity of the high pressure closed.
Fibrinolysis and Hyperfibrinolysis TEG Analysis
Hematology Blueprint PANCE Blueprint. Coagulation Disorders.
Drugs Susan Louw Haematology Registrar. 4 Questions to ask: Can I stop? (What is the risk of thrombosis?) Should I stop? (What is the risk of bleeding?)
Blunt Aortic Injury with Concomitant Intra-abdominal Solid Organ Injury: Treatment Priorities Revisited Santaniello J, et al, The Journal of TRAUMA Injury,
DIC. acute, subacute or chronic widespread intravascular fibrin formation in response to excessive blood protease activity that overcomes the natural.
Implementation of RRT improved the survival rate significantly, when blood urea nitrogen or serum creatinine was still low level. However, most of those.
Hemostatic process 1- Vascular Consrriction 2- Platelet plug formation 3- Fibrin formation ( Coagulation ) 4- Fibrinolysis.
Thrombocytopenia in Critically Ill Patients Receiving Thromboprophylaxis Frequency, Risk Factors, and Outcomes David R. Williamson, BPharm, MSc ; Martin.
Haemostasis. Indications for hemostasis test – Identify patients presenting with bleeding that have a correctable bleeding tendency – Identify patients.
Chapter 38 Hematologic Disorders and Oncologic Emergencies Unit 8 Multisystem Alterations Seventh Edition Linda D. Urden Kathleen M. Stacy Mary E. Lough.
Nursing Management: Hematologic Problems Chapter 31 Overview Copyright © 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc.
Dr Michelle Webb Renal Consultant, Associate Medical Director Patient Safety, East Kent Hospitals University NHS Foundation Trust and Co-lead for Sepsis.
Risk Factors and Outcome of Changes in Adrenal Response to ACTH in the Course of Critical Illness Margriet Fleur Charlotte de Jong, MD, PhD, Albertus Beishuizen,
Treatment and Prevention of Heparin- Induced Thrombocytopenia Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Coagulation tests CBC- complete blood count
Alcohol dependence is independently associated with sepsis, septic shock, and hospital mortality among adult ICU patients Crit Care Med 2007 ; 35 :
STAFFORDSHIRE THROMBOSIS AND ANTICOAGULATION CENTRE (STAC) PATIENT SPECIFIC DIRECTION FOR DALTEPARIN (LMWH) FOR PATIENTS WITH VENOUS THROMBO-EMBOLISM (VTE)/MECHANICAL.
Types of Apheresis Blood taken from a healthy donor can be separated into its component parts during blood donation, where the needed component is collected.
Management Control or elimination of the underlying cause Severe DIC: – Control of hemodynamic parameters – Respiratory support – Surgery Attempts to treat.
Plasma and plasma components in the management of disseminated intravascular coagulation Marcel Levi* Academic Medical Center, University of Amsterdam,
Risk Factors for Linezolid-Associated Thrombocytopenia in Adult Patients Cristina Gervasoni Ospedale Luigi Sacco, Milano.
Obada Al-Eisa Saud Bashtawy Emad Mansour.  It is an acquired condition characterized by massive activation of the coagulation system.  It is always.
Heparin-Induced Thrombocytopenia Farzaneh Dastan Assistant Professor of Pharmacotherapy, Pharm D, BCPS SBMU.
An AKI project for critically ill cancer patients
Yadegarynia, D. MD..
Thrombocytopenia Allen Chang, PGY2 5/18/15.
Treatment and Prevention of Heparin-Induced Thrombocytopenia
AKI in critically ill cancer patients:
Approach to Thrombocytopenia
Aprotinin Emily Sarver 11/20/2018.
The Hematologic System as a Marker of Organ Dysfunction in Sepsis
PROPPR Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma. 
Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with.
Anemia of chronic disease =Anemia of chronic disorders (ACD)
Drugs Affecting Blood.
How I treat heparin-induced thrombocytopenia and thrombosis
Presentation transcript:

Diana Escobar Azusa Pacific University

Authors: Thiele, Thomas, Kathleen Selleng, Sixten Selleng, Andreas Greinacher, &Tamam Bakchoul July 2013 Source: International Seminar of Hematology Database: MEDLINE

 Thrombocytopenia (TCP) is commonly defined as a platelet count of <150,000 plts, some apply the cut-off at <100,000 plts, and even further to <50,000plts in patients ◦ Platelet number alone is not definitive  Compare to the patient’s baseline & nadir  Analyze timing of decrease & overall trend  Also analyze a lack of rise in plt ct.

Common Causes

1. Hemodilution 2. Increased platelet consumption ◦ Due to massive trauma, bleeding, sepsis, DIC 3. Decreased platelet production 4. Increased platelet sequestration 5. Platelet destruction by immune mechanisms  Pseudothombocytopenina: “Idiopathic” ◦ develops in 2.5% of pts taking grycoprotein Iib/IIIa antagonists: abciximab, integrilin, tirofiban  Dx: repeated blood counts in citrated or heparinized blood

 In order to correctly identify, nurses must be familiar with the “normal” platelet trends in ICU patients with differing conditions. ◦ i.e.: trauma, major/minor surgery, medical.  Postsurgical: Expected Plt ct. decline between D1-D4 ◦ Magnitude reflects the extent of tissue trauma/blood loss  Plt. Consumption ◦ Should reach pre-surgery level between D5-D7, peak at D14

 *Post-Trauma: Critically injured pts: almost normal Plt cts at admission w/ rapid Plt decrease during first hrs ◦ *Plt ct <50,000 &/or delay in Plt. Recovery  associated with high mortality  *Medical: Plt. ct depends on underlying disease ◦ Predisposing conditions: Sepsis, DIC, Renal Replacement Therapy, Extracorporeal circuits, Intravascular devices, Multi-organ Failure, & recent CPR  Recent study of 243 ICU Pts  In medical pts. Plt recovery expected w/in 5D (90%), with proper treatment of underlying disease  Higher morbidity/mortality is Plt recovery delayed >4D  Persistent TCP at D14  mortality rt of 66% vs. 16% with normal Plt ct. Median Plt increase expected in ICU pts of ~30 x 10 ∧ 9/ L/D in survivors

 Monitor closely the trends in Plt recovery and be alert for any sudden decrease after initial recovery  Acute TCP can result from: ◦ Sepsis, acute infection, acute leukemia, severe thromboembolism, intoxication: alcohol, drug side- effects  Be alert for: ◦ Rapid decrease w/in hrs after several days in ICU w/out reason  Dx: Plt trends, baseline, nadir, plt specifics

 Trauma: concomitant treatment for hemodilution, hypothermia, loss of clotting factors and platelets, hyperfibrinolysis ◦ Early Plt transfusions w/RBCs for major trauma  DIC: Manage underlying conditions and causes, platelet transfusions only given in cases w/high risk for bleeding  Sepsis: correlated with adverse outcomes, but not a cause, therefore Tx underlying infection  Intoxication: ◦ Chronic Alcohol abuse due to Plt sequestration in spleen (splenomegaly)

 Intoxication… ◦ Drugs (Non-Immune Pathogenesis): adverse drug reactions in 20% hospital pts. (effects on megakaryocytes)  Study of 3,496 pts finds:  Histamine H2 Antagonists  Nonsteroidal anti-inflammatory drugs  Unfractionated heparin  Acetaminophen (3.4% pts), valproate, carbamazepine, phenobartital, phenytoin (1%pts) ◦ Herbals: take detailed Hx ◦ Venoms: activate clotting cascade ◦ Treatment: charcoal ingestions, dialysis, antidote administration, d/c medications

 Immune: Plt ct fall to <5,000 w/in 24-48hrs w/bleeding symptoms or if Plt ct decreases 50%+ in 2 nd week of Tx ◦ Immune mediated Drug-Induced Thrombocytopenia (DITP)  Dx: Need lab tests of drug-dependent antibodies  Tx: D/C drugs immediately  Most Common Drugs:  Vancomycin, Penicillin, trimethoprim/sulfamethozazole, ceftriaxone, ibuprofen, meirtazapine

 Drug: Heparin Induced TCP (HIT) ◦ Drug-mediated, prothromboric disorder b/c immunization against Plt. Factor 4  S/S: Plt ct fall >50% from the highest value after start of Heparin Tx and/or a new thrombosis occurring 5-14D after Tx ◦ Incidence of HIT is low in ICU according to study  N= ICU pts w/ incidence confirmed in 0.5% pts  Dx depends on scoring results of: Thrombocytopenia, Timing, Thrombosis, & oThers (4Ts Test/HEP Test)  Tx: d/c heparin, use low molecular weight heparin delteparin, use non-heparin anticoagulants

 What are the 3 most common causes of TCP in ICU patients? A. HIT, sepsis, trauma B. Trauma, DIC, sepsis C. Trauma, surgery complications, sepsis D. Intoxication, trauma, Immune response

 What are the three most common causes of TCP in ICU patients? A. HIP, sepsis, trauma B. Trauma, DIC, sepsis C. Trauma, surgery complications, sepsis D. Intoxication, trauma, Immune response

 True or False: Platelet transfusion is the first line treatment for patients with Thrombocytopenia

 False, first line treatment should be to target and treat underlying disease, platelet transfusions are only indicated bleeding patients or invasive procedures

Thiele, T., Selleng, K., Selleng, S., Greinacher, A., & Bakchoul, T. (2013). Thrombocytopenia in the intensive care unit-diagnostic approach and management. Seminars In Hematology, 50(3), doi: /j.seminhematol